Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.19.01389
Abstract: PURPOSE Patients with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) have a poor prognosis, and their treatment represents an urgent and unmet need. Because PMBCL is associated with genetic aberrations at 9p24 and… read more here.
Keywords: response; keynote 170; refractory primary; cell ... See more keywords